SCHEMBL6031111

SCHEMBL6031111

[O]c1ccc2[nH]c(=O)ccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.62
CA9 Q16790 2/20 0.62
F11 P03951 1/20 0.62
CA1 P00915 1/20 0.54
CA3 P07451 1/20 0.54
CA4 P22748 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA7 P43166 1/20 0.54
CA13 Q8N1Q1 1/20 0.54
CA14 Q9ULX7 1/20 0.54
CA5B Q9Y2D0 1/20 0.54
AR P10275 1/20 0.49
PDE3B Q13370 2/20 0.47
PDE3A Q14432 2/20 0.47
MAPK1 P28482 1/20 0.46
MAPT P10636 4/20 0.42
PKM P14618 1/20 0.42
IDO1 P14902 1/20 0.41
TBXAS1 P24557 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434300 0.77 CA12 (1.00) CA12CA9F11CA1CA3
SCHEMBL607156 0.77 CA12 (0.60) CA12CA9F11CA1CA3
SCHEMBL1771379 0.77 CA12 (0.60) CA12CA9F11CA1CA3
SCHEMBL3368797 0.77 CA12 (0.60) CA12CA9F11CA1CA3
SCHEMBL1052487 0.77 F11 (1.00) CA12CA9F11CA1CA3
SCHEMBL786595 0.77 CA12 (0.60) CA12CA9F11CA1CA3
SCHEMBL347122 0.77 CA12 (0.60) CA12CA9F11CA1CA3
SCHEMBL14279696 0.77 CA12 (0.60) CA12CA9F11CA1CA3
SCHEMBL1771772 0.77 CA12 (0.60) CA12CA9F11CA1CA3
SCHEMBL17951770 0.77 MAPK1 (0.68) CA12CA9F11CA1CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094710-A1 Piperidine-pyridazones and phthalazones as pde4 inhibitors ALTANA PHARMA AG (DE) 2006-05-04 US claimed
EP-1556049-A1 PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS ALTANA Pharma AG (DE) 2005-07-27 EP claimed
WO-2004017974-A1 PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-04 WO claimed
US-20060094710-A1 Piperidine-pyridazones and phthalazones as pde4 inhibitors ALTANA PHARMA AG (DE) 2006-05-04 US disclosed
EP-1556049-A1 PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS ALTANA Pharma AG (DE) 2005-07-27 EP disclosed
WO-2004017974-A1 PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094710-A1 Piperidine-pyridazones and phthalazones as pde4 inhibitors PDE4A, PDE4B, PDE3A CA12 4223/4885CA9 2011/4885F11 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.